We report a patient with advanced hormone-positive, HER2-negative breast cancer with contralateral supraclavicular node and subpleural lung nodules who was treated with letrozole and palbociclib with palliative intent. After 2 years of treatment, PET–CT showed disease confined only to the breast and she underwent modified radical mastectomy. Histopathology showed a 1-mm focus of invasive carcinoma. She was continued on letrozole and palbociclib and has completed 3 years since the diagnosis of metastatic disease and is in complete remission.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Rastogi S, Gulia S, Bajpai J, Ghosh J, Gupta S. Oligometastatic breast cancer: a mini review. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol. 2014;35:203–6.
Badwe R, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.
Soran A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25:3141–9.
Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial surgery and survival in stage IV breast cancer in the United States, 1988–2011. JAMA Surg. 2016;151:424–31.
Xie Y, et al. Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: a retrospective analysis. Medicine (Baltimore). 2017;96:e7048.
Milano MT, et al. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2019;131:45–51.
Trovo M, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177–80.
Rugo HS, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–29.
Diéras V, et al. Palbociclib with letrozole in postmenopausal women with ER+/HER2− advanced breast cancer: hematologic safety analysis of the randomized PALOMA‐2 trial. Oncologist. 2019;24:1514–25. https://doi.org/10.1634/theoncologist.2019-0019.
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dhanushkodi, M., Velusamy, S. Long-Term Survival of Advanced Breast Cancer with Letrozole and Palbociclib: Can the Intent Change from Palliation to Cure?. Indian J Gynecol Oncolog 18, 28 (2020). https://doi.org/10.1007/s40944-020-0376-0
- Advanced breast cancer
- Letrozole and palbociclib
- Long-term survival